World Health Organization (WHO) is recommending widespread use of the RTS,S/AS01 (RTS,S) malaria vaccine among children in sub-Saharan Africa and in other regions with moderate to high P. falciparum malaria transmission. The recommendation is based on results from an ongoing pilot programme in Ghana, Kenya & Malawi that has reached more than 800 000 children since 2019.
The vaccine is developed by British drugmaker GlaxoSmithKline (GSK). Many vaccines exist against viruses and bacteria but this was the first time that the WHO recommended broad use of a vaccine against a human parasite. The vaccine acts against Plasmodium falciparum, one of five parasite species and the most deadly. The symptoms of malaria are fever, headaches, and muscle pain, then cycles of chills, fever, and sweating.
Important takeaways for all competitive exams:
The Reserve Bank of India (RBI) has issued final directions allowing higher loan-to-value (LTV) ratios…
In a major leadership transition, Sun Pharmaceutical Industries Ltd, India’s largest pharmaceutical company, has appointed…
In a major boost for job seekers across India, Apna.co, one of the country's leading…
In a major move to align India’s youth with the global green economy, Shell India…
The Department of Administrative Reforms and Public Grievances (DARPG) has released its 34th monthly report…
The Inland Fisheries and Aquaculture Meet 2025 was held in Indore, Madhya Pradesh on June…
